Chedid F, Fudge A, Teubner J, James S L, Simmer K
Department of Paediatrics, Flinders Medical Centre, Bedford Park, South Australia.
J Paediatr Child Health. 1991 Jun;27(3):164-6. doi: 10.1111/j.1440-1754.1991.tb00378.x.
The use of aluminium-containing medications and aluminium contamination of infant formulae is common. We aimed to determine whether aluminium absorption occurs after antacid ingestion. Plasma and urinary levels of aluminium were measured before and after antacid therapy in seven infants whose mean gestational age was 36 +/- 2 weeks and postnatal age 11 +/- 5 days. Antacid therapy (400-800 mumol aluminium) was given with feeds for 2 days. Plasma aluminium levels increased and reached toxic levels (0.64 +/- 0.33 mumol/L vs 3.48 +/- 2.86 mumol/L, P = 0.029). Urinary aluminium: creatinine ratio also increased. These results demonstrate that infants absorb aluminium from antacids and raise the concern of aluminium toxicity.
含铝药物的使用以及婴儿配方奶粉受到铝污染的情况很常见。我们旨在确定服用抗酸剂后是否会发生铝吸收。对7名平均胎龄为36±2周、出生后年龄为11±5天的婴儿在抗酸治疗前后测量了血浆和尿液中的铝水平。抗酸治疗（400 - 800微摩尔铝）随喂养给予2天。血浆铝水平升高并达到中毒水平（0.64±0.33微摩尔/升对3.48±2.86微摩尔/升，P = 0.029）。尿铝：肌酐比值也升高。这些结果表明婴儿会从抗酸剂中吸收铝，并引发了对铝毒性的担忧。
